Project Grant R01AA032636
Award Date 9/20/25
Completion Date 6/30/30
Dollars Obligated $902K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $390,454 Project Grant to Envisbio LLC to develop novel therapeutic aptamers targeting phosphodiesterase 4B (PDE4B) for the treatment of alcohol use disorder (AUD). The project aims to identify and characterize PDE4B-specific aptamers that can modulate PDE4B activity, with the goal of advancing these modulators into in vivo testing and eventual human clinical trials for...
- This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) program, supports a $559,180 research project to investigate neurobiological factors underlying Alcohol Use Disorder (AUD) with and without comorbid cigarette smoking. The project aims to identify AUD-associated differences in DNA methylation and RNA expression in the nucleus accumbens and dorsolateral prefrontal cortex, key brain regions...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $999,393 Cooperative Agreement to Stress Therapeutics, Inc., a California-based pharmaceutical company, to conduct Investigational New Drug (IND)-enabling studies for a novel therapeutic to treat Alcohol Use Disorder (AUD). The key products and services to be delivered include: 1) Manufacture and validation of the test article for IND-enabling studies; 2) Development and...
- This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) provides $3,168,729 to New York University to conduct a collaborative research project titled "A Translational Approach for Novel Precision Medicine Models." The project aims to identify novel molecular targets and mechanisms of treatment responses in alcohol use disorder (AUD) based on the role of mitochondrial metabolism and epigenetic...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $399,076 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Tennessee Health Science Center in Memphis, TN. The purpose of this grant is to develop a rapid and reliable platform for evaluating and repurposing FDA-approved drugs to target chronic alcohol tolerance and dependence associated with Alcohol Use Disorder (AUD). The project will leverage the nematode Caenorhabditis elegans as an...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $914,324 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Demerx, Inc. in Miami, FL. The grant supports the investigational new drug development of noribogaine for the treatment of alcohol use disorder (AUD). Key details include: Demerx, Inc. is a clinical-stage drug development company advancing noribogaine, a novel "psychoplastogen" therapeutic agent, for the treatment of AUD. The grant will...
- This Project Grant award, totaling $755,539, was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273). The funding will support research conducted by Emory University to evaluate the real-world utilization, effectiveness, and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a treatment for alcohol use disorder (AUD). The project aims to leverage administrative claims data and linked electronic health records...
- This federal Cooperative Agreement award of $1,001,425.00 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, aims to develop a novel and functionally selective 5-HT2C receptor agonist for treating Alcohol Use Disorder (AUD). The project's goal is to confirm and extend the drug candidacy of KB128, a proprietary compound developed by Kuleon LLC, as a potential therapeutic medication for AUD. The award will...
- This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...
- Under a $368,673 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded on September 25, 2023, Artiam Bio Inc., a minority-owned small disadvantaged biotechnology company, is developing and evaluating second-generation partial inverse agonists targeting the type 1 cannabinoid (CB1) receptor as a potential therapy for alcohol use disorder (AUD). Artiam Bio is conducting preclinical efficacy studies of its lead CB1 receptor partial inverse agonist compound in rat...